A New Dawn-Using Teletrials for Early Phase Drug Development: A Practical Guideline

Area of Science:

• Oncology
• Clinical Trial Design
• Health Equity

Background:

• Early-phase cancer clinical trials disproportionately benefit urban populations, creating access inequities for regional/rural (R/R) patients.
• Travel burdens significantly hinder R/R participation in early drug development (EDD) trials.
• Policy pressures are driving innovative solutions to enhance clinical trial accessibility.

Purpose of the Study:

• To provide practical guidelines for implementing the teletrial model in early drug development (EDD) trials.
• To address recruitment challenges and improve access to phase 1 cancer studies.
• To adapt the teletrial model, proven in later-phase studies, for the complexities of early-phase research.

Main Methods:

• Review of operational, regulatory, and logistical factors for phase 1 teletrials.
• Evaluation of site assessment, ethical governance, resource allocation, and funding.
• Integration of lessons learned from pilot teletrial initiatives.

Main Results:

• Outlined key considerations for establishing phase 1 teletrials.
• Presented adaptable teletrial frameworks for diverse satellite site capabilities.
• Provided recommendations for trial design and site conversion based on pilot successes.

Conclusions:

• Phase 1 teletrials represent a critical advancement for equitable access to cancer therapies.
• Challenges like resource needs and costs are acknowledged but manageable with planning.
• Teletrials boost recruitment, improve R/R patient access, and reduce geographic disparities, vital for rare-disease and biomarker-driven studies.